利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.034 秒)

    1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    4.
    发明申请
    1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
    作为固体脱乙酰基酶6抑制剂的1,3,4-氧杂衍生化合物和包含其的药物组合物

    公开(公告)号：WO2017023133A2

    公开(公告)日：2017-02-09

    申请号：PCT/KR2016/008622

    申请日：2016-08-04

    申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

    发明人： LEE, Jaekwang ,  KIM, Yuntae ,  LEE, Chang Sik ,  SONG, Hyeseung ,  GWAK, Dal-Yong ,  LEE, Jaeyoung ,  OH, Jung Taek ,  LEE, Chang Gon ,  KIM, II Hyang

    CPC分类号： C07D271/10 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/10 ,  C07D491/10

    摘要： The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de¬ formations and chromosomal abnormalities.

    摘要翻译： 本发明涉及具有组蛋白脱乙酰酶6（HDAC6）抑制活性的新化合物，其立体异构体或其药学上可接受的盐，其用于制备治疗药物的用途，含有它们的药物组合物，使用 组合物和制备新化合物的方法。 本发明的新型化合物，其立体异构体或其药学上可接受的盐具有组蛋白脱乙酰酶（HDAC）抑制活性，对预防或治疗HDAC6介导的疾病包括感染性疾病有效; 肿瘤; 内分泌，营养和代谢疾病; 精神和行为障碍; 神经系统疾病; 眼睛和附件疾病; 心血管疾病; 呼吸疾病; 消化系统疾病; 皮肤和皮下组织的疾病; 肌肉骨骼系统和结缔组织的疾病; 或先天性畸形，形成和染色体异常。

    OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    8.
    发明申请
    OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
    恶二唑胺衍生物化合物作为组蛋白脱乙酰酶6的抑制剂，以及包含该组合物的药物组合物

    公开(公告)号：WO2017065473A1

    公开(公告)日：2017-04-20

    申请号：PCT/KR2016/011355

    申请日：2016-10-11

    申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

    发明人： KIM, Yuntae ,  LEE, Chang Sik ,  OH, Jung Taek ,  SONG, Hyeseung ,  CHOI, Jin ,  LEE, Jaeyoung

    IPC分类号： C07D413/04 ,  C07D271/10 ,  C07D271/06 ,  C07C211/33 ,  C07C211/35 ,  A61K31/4245 ,  A61K31/506

    CPC分类号： C07D271/10 ,  C07D413/04 ,  C07D413/14

    摘要： The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

    摘要翻译： 本发明涉及具有组蛋白脱乙酰酶6（HDAC6）抑制活性的新化合物，其立体异构体或其药学上可接受的盐，其在制备治疗药物中的用途，含有其的药物组合物， 使用该组合物治疗疾病的方法，以及制备该新化合物的方法。 本发明的新化合物，其立体异构体或其药学上可接受的盐具有组蛋白脱乙酰酶（HDAC）抑制活性，并且可有效预防或治疗HDAC6介导的疾病，包括感染性疾病; 肿瘤; 内分泌，营养和代谢疾病; 精神和行为障碍; 神经疾病; 眼睛和附属器疾病; 心血管疾病; 呼吸疾病; 消化系统疾病; 皮肤和皮下组织疾病; 肌肉骨骼系统和结缔组织疾病; 或先天性畸形，畸形和染色体异常。